Searchable abstracts of presentations at key conferences in endocrinology

ea0047oc26 | Spotlight on Prostate Cancer | Theranostics2016

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy and quality of life assessment

Yadav Madhav , Ballal Sanjana , Tripathi Madhavi , Damle Nishikant , Bal Chandrasekhar

Purpose: The purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer (mCRPC).Methods: 31 mCRPC patients with progressive disease despite second line hormonal therapy and/or Docetaxel chemotherapy were recruited for the study. All patients underwent diagnostic68Ga-PSMA-HBED-CCPET/CT, prior to inclusion for therapy. Inclu...